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Objectives.T h e−420C > G polymorphism located in the resistin gene (RETN) promoter has recently been suggested to play
a potential role in proinﬂammatory conditions and cardiovascular disease. This study investigated the association of the RETN
promoter polymorphism with Kawasaki disease (KD) and its clinical parameters in Chinese children. Methods. We compared
patients with complete KD to incomplete KD children. Genotyping of the RETN promoter polymorphism was performed using
MassARRAY system, and serum resistin levels were estimated using the sandwich enzyme immunoassay method. Results.T h e r e
was no signiﬁcant diﬀerence in RETN (−420C > G) genotypes between KD and control groups. However, the frequency of the
G allele was higher in iKD patients than in cKD children due to a signiﬁcantly increased frequency of the GG genotypes. Serum
levels of resistin were signiﬁcantly higher in KD patients than in controls regardless of the presence of coronary artery lesions
(CALs). Conclusion. The present ﬁndings suggest that while resistin may play a role in the pathogenesis of KD, there is no apparent
association between CAL and the RETN (−420C > G) gene polymorphism in KD children. However, the diagnosis of iKD is
challenging but can be supported by the presence of the G allele and the GG genotypes.
1.Introduction
Kawasaki is an acute systemic vasculitis that predominantly
aﬀects infants and young children. The most serious com-
plication of KD is the occurrence of coronary artery lesions
(CAL), including myocardial infarction, coronary artery
ﬁstula formation [1], coronary artery dilatation, or coronary
artery aneurysm [2]. Some evidence suggests that the excess
production of inﬂammatory mediators is involved in the
pathology of KD [3].
Although more than 40 years have passed since the
ﬁrst description of KD [4], no speciﬁc laboratory markers
have been identiﬁed to date, and the diagnosis consequently
rests on the clinical ﬁndings. Some patients fail to meet all
the criteria [2] for KD but are nevertheless at risk for the
development of coronary artery disease. These incomplete
forms of KD (iKD) are being increasingly reported, although
nocleardeﬁnitionhasbeendeveloped[2,5].Inpatientswith
iKD, the diagnosis is challenging and therapeutic decisions
are diﬃcult.
Resistin, a novel adipocyte-derived peptide, belongs to a
family of cysteine-rich secretory proteins [6]. In humans, the
peptide is expressed in monocytes and macrophages [7], and
it is considered to be involved in the pathogenesis of inﬂam-
mation [8], coronary artery calciﬁcation [9], atherosclerosis,
and acute coronary syndrome [10].
RETN, the gene coding for human resistin, is located on
chromosome 19p13.3 [6]. To date, several single-nucleotide
polymorphisms in the RETN gene have been described [11,
12]. One of the most frequently studied polymorphisms,
RETN −420C > G (rs1862513), was reported to be associ-
ated with the regulation of RETN gene expression and serum
resistin level [13–15]. Several studies have also associated
the RETN −420C > G polymorphism with arteriosclerosis,2 Mediators of Inﬂammation
coronary artery disease [16] and cerebrovascular disease
[17]. To our knowledge, no data have been published on the
associationoftheRETN −420C > Gpolymorphismwiththe
risk of KD.
In this study, we hypothesized that the genetic poly-
morphisms of RETN −420C > G was associated with KD
susceptibility and/or CAL formation. We investigated the
association of RETN −420C > G polymorphisms in the
susceptibility of KD (cKD and iKD) patients and control
subjects as well as KD patients with and without CAL
formation.
2.SubjectsandMethods
2.1. Subjects and Data Collection. We enrolled patients with
KD from the Children’s Hospital of Chongqing Medicine
University, Chongqing, China. The study group included 91
patients (58 males and 33 females, 3.31 ± 2.74 year old); all
of whom met the criteria proposed by the Japanese Kawasaki
Disease Research Committee [18]. According to the criteria
of KD, there were 91 identiﬁed patients, classiﬁed as cKD
(n = 57) or iKD (n = 34), cKD was deﬁned as a fever and
at least four of the ﬁve principal criteria [2], and iKD only
meet as fever persisting at least 5 days and one to three prin-
cipal criteria. These patients were treated with oral aspirin
and 1 or 2g/kg intravenous immune globulin after admis-
sion. Sixty-eight patients (74.7%) responded to intravenous
immuneglobulininfusion.Inaddition,115sex-age-matched
healthy blood subjects were used as healthy controls. The
study protocol was approved by the Ethics Committee of
the Chongqing Medicine University, and written informed
consents were obtained from the parents of all subjects.
Echocardiography was obtained within 2 weeks of the
onset or before intravenous immunoglobulin administra-
tion. CALs were deﬁned as coronary vessel internal diameter
≥2SDs above the mean for age adjusted for body surface area
(BSA) [19]. Patients were divided into two groups according
tothepresenceofCAL:35patientswithCALsand56patients
without CALs.
Laboratory data were obtained for each child, including
white blood cell (WBC) counts, red blood cell (RBC) counts,
hemoglobin (HB), platelet count, alanine aminotransferase
(ALT) level, aspartate aminotransferase (AST) level, C-
reactive protein (CRP), and erythrocyte sedimentation rate
(ESR). All blood samples were drawn before IVIG therapy in
the KD patient group.
2.2. Sample Collection and Processing. Venous blood samples
were obtained from patients and healthy subjects. For bio-
chemical analysis, blood samples were allowed to clot at
room temperature, then immediately centrifuged to separate
serum, and kept at −80◦C. For molecular study, blood
samples were collected in ethylenediaminetetraacetic acid
(EDTA) tubes to prevent the coagulation of blood samples.
Genomic DNA was extracted from whole blood using
standard phenol-chloroform extraction technique.
2.3. Measurement of Serum Resistin Levels. Resistin levels
from the serum samples were determined using com-
mercial immunoassay kit according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA), as
described previously [20]. Resistin standards were run on
microTest plates, and the antigen concentration (ng/mL)
was determined from the standard curve using the AMP
Diagnostics ELISA reader (Austria).
2.4. Genotyping of the RETN −420C/G Polymorphism. SNP
genotyping was done using MassARRAY system (Sequenom)
by means of matrix-assisted laser desorption ionisation-
time of ﬂight mass spectrometry method (MALDI-TOF)
according to the manufacturer’s instructions (Shanghai
Benegene Biotechnology Co., Ltd). Genotype calling was
performedinrealtimewithMassARRAYRTsoftwareversion
3.0.0.4 and analyzed using the MassARRAY Typer software
version 3.4 (Sequenom).
2.5. StatisticalAnalysis. Clinical phenotypes, including WBC
counts, platelet counts, RBC counts, HB levels, platelet
count, ALT level, AST level, CRP, and ESR, were each
analyzed as a quantitative trait. All values in this study are
described as mean ± standard deviation (SD). Statistical sig-
niﬁcance of the diﬀerences between the continuous variables
was evaluated by Student’s t-test or the Mann-Whitney test.
Analysis of variance (ANOVA) followed by Scheﬀe’s test was
used for analysis of the serum levels of each genotype. The
probability values presented are based on two-sided tests.





3.1. Clinical Characteristics of Study Subjects. As shown in
Table 1, platelet count, WBC counts, RBC counts, ALT level,
AST level, CRP, and ESR were higher in KD patients
compared to controls (P<0.001), whereas hemoglobin and
HB levels were signiﬁcantly lower in KD patients compared
to controls (P<0.05).
The comparison of parameters between patients with
CALs and patients without CALs was presented in Table 2.
There were no signiﬁcant diﬀerences between two groups in
age, ALT, AST, CRP, platelet count, WBC counts, and ESR
levels but HB levels (P<0.05).
The characteristics of cKD patients and iKD groups are
presented in Table 3. Compared with cKD groups signiﬁcant
lower CRP (P<0.001) and higher HB levels and platelet
count (P all <0.05) were noted in patients with iKD.
3.2. Allele Frequencies of the RETN (−420C/G) Polymor-
phism in KD and Control Subjects. Ninety-one children
with KD and 115 healthy children were genotyped at the
RETN (−420C/G) polymorphism, and allele frequencies
were examined. The genomic frequencies of the RETN
(−420C/G) polymorphism in children with KD were 17.6%Mediators of Inﬂammation 3
Table 1: Comparison of laboratory characteristic of patients and control groups.
KD (cKD and iKD n = 91) Controls (n = 115) P
Age at diagnosis (yr) 3.31 ±2.74 2.10 ±1.04 0.232
Sex (male/female) 58/33 75/40 0.557
Hemoglobin (g/L) 103.60 ±8.86 124.02 ±16.84 <0.001
Platelet (103/uL) 427.24 ±162.57 255.87 ±43.49 <0.001
WBC (103/uL) 13.02 ±6.06 7.35 ±1.40 <0.001
RBC (106/mm3)3 .97 ±0.49 4.43 ±0.29 <0.001
AST (U/L) 57.05 ±86.80 17.60 ±6.49 <0.001
ALT (U/L) 85.19 ±107.69 27.6 ±6.80 <0.001
CRP (mg/dL) 47.29 ±51.61 4.39 ±1.30 <0.001
ESR (mm/hr) 55.97 ±27.21 7.89 ±3.30 <0.001
Resistin (ng/mL) 22.24 ±14.32 8.24 ±7.88 <0.001
Notes: KD, Kawasaki disease; yr, year; WBC, white blood cell counts; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; red blood cells counts
(RBC); alanine aminotransferase (ALT) level; aspartate aminotransferase (AST). P value is for comparison between control and patients.
Table 2: Relation between clinical parameters in KD patients and development of CALs.
KD with CALs (n = 35) KD without CALs (n = 56) P
Age at diagnosis (yr) 2.99 ±2.79 3.52 ±2.31 0.463
Hemoglobin (g/L) 101.31 ±10.25 107.16 ±10.06 0.048
Platelet (103/uL) 418.60 ±183.58 419.05 ±188.85 0.993
WBC (103/uL) 14.50 ±5.71 11.12 ±7.30 0.066
RBC (106/mm3)3 .99 ±0.55 3.98 ±0.51 0.988
AST (U/L) 53.32 ±83.94 57.82 ±75.58 0.853
ALT (U/L) 75.62 ±87.06 90.23 ±128.25 0.633
CRP (mg/dL) 45.29 ±46.03 52.21 ±63.16 0.646
ESR (mm/hr) 52.89 ±30.60 49.59 ±25.80 0.730
Resistin (ng/mL) 34.91 ±20.97 20.01 ±15.51 0.066
Notes: CAL: coronary artery lesion; P value is for comparison between patients with CALs and these without CALs.
Table 3: Clinical and laboratory variables at admission in the groups with complete and incomplete KD.
Complete KD (n = 57) Incomplete KD (n = 34) P
Age at diagnosis (yr) 3.09 ±2.40 3.82 ±3.74 0.433
Hemoglobin (g/L) 101.49 ±9.94 109.92 ±10.04 0.012
Platelet (103/uL) 389.88 ±183.28 522.25 ±149.65 0.026
WBC (103/uL) 13.31 ±6.71 18.41 ±4.30 0.174
RBC (106/mm3)3 .93 ±0.52 4.19 ±0.53 0.128
AST (U/L) 59.82 ±88.82 35.11 ±20.20 0.414
ALT (U/L) 91.62 ±109.06 34.23 ±32.25 0.136
CRP (mg/dL) 58.42 ±54.81 13.63 ±15.10 0.000
ESR (mm/hr) 52.92 ±26.60 36.59 ±10.80 0.550
Resistin (ng/mL) 17.01 ±13.13 24.41 ±16.38 0.155
Note: P value is for comparison between groups with complete and incomplete KD.
(16/91) for CC, 46.2% (42/91) for CG, and 36.3% (33/91)
for GG. In controls, these frequencies were 12.2% (14/115)
for CC, 45.2% (52/115) for CG, and 42.6% (49/115) for GG.
The genomic and allelic frequencies at this polymorphism
did not signiﬁcantly diﬀer between children with KD and
control subjects (Table 4).
3.3. Allele Frequencies of the RETN (−420C/G) Polymorphism
in KD Children with and without Coronary Lesions. The
frequency of the combined CG + CC genotype was 67.9%
(38/56) in KD patients without CALs and 74.3% (26/35) in
KD patients with CALs. There was no signiﬁcant diﬀerence
in genotype between KD children with and without CALs4 Mediators of Inﬂammation
Table 4: RETN (−420C > G) genotype and allele frequency in KD patients and controls.
KD (n = 91) n (%) Control (n = 115) n (%) P value OR (95% CI)
Allele C 74 (0.407) 80 (0.348)
G 108 (0.593) 150 (0.652) 0.221 1.285 (0.860–1.919)
Genotypes
CC 16 (0.176) 14 (0.122)
GG 33 (0.363) 49 (0.426)
CG 42 (0.462) 52 (0.452) 0.462
Genotypes GG 33 (0.363) 49 (0.426)
CC + C G 58 (0.637) 66 (0.574) 0.356 0.766 (0.436–1.413)
Notes: RETN: resistin gene; OR: odds ratio; CI: conﬁdence interval. P value is for comparison between control and patients.
Table 5: RETN (−420C > G) genotype and allele frequency in the groups with CALs and without CALs.
KD with CALs (n = 35) n (%) KD without CALs (n = 56) n (%) P value OR (95% CI)
Allele C 34 (0.486) 44 (0.393)
G 36 (0.514) 68 (0.607) 0.297 0.685 (0.336–1.397)
Genotypes
CC 8 (0.229) 6 (0.107)
GG 9 (0.257) 18 (0.514)
CG 18 (0.514) 32 (0.571) 0.442
Genotypes GG 9 (0.257) 18 (0.321)
CC + CG 26 (0.743) 38 (0.679) 0.575 1.368 (0.457–4.099)
Note: P value is for comparison between patients with CALs and these without CALs.
Table 6: RETN (−420C > G) genotype and allele frequency in the groups with complete and incomplete KD.
Complete KD (n = 57) n (%) Incomplete KD (n = 34) n (%) P value OR (95% CI)
Allele C 56 (0.490) 20 (0.294)
G 58 (0.510) 48 (0.706) 0.048 2.302 (0.995–5.328)
Genotypes
CC 11 (0.188) 4 (0.118)
GG 12 (0.208) 18 (0.529)
CG 34 (0.604) 12 (0.353) 0.044
Genotypes GG 12 (0.208) 18 (0.529)
CC + CG 45 (0.792) 16 (0.471) 0.012 0.234 (0.072–0.761)
Note: P value is for comparison between groups with complete and incomplete KD.
(Table 5). These results suggest that the RETN (−420C/G)
polymorphism may not be associated with the development
of CALs in Chinese children with KD.
3.4. Allele Frequencies of the RETN (−420C/G) Polymorphism





revealed that signiﬁcantly more iKD than cKD patients were
homozygous for the G allele (aOR 2.302, 95% CI 0.995–5.38;
Table 6).
3.5. Allele Frequencies of the RETN (−420C/G) Polymorphism
in Responders and Nonresponders to Intravenous Immune
Globulin Therapy. There was no signiﬁcant diﬀerence in
genomic frequencies and genotype between responders and
nonresponders (Table 7).
3.6. Association between the RETN (−420C/G) Polymorphism
and Clinical Parameters in Children with KD. There were
no signiﬁcant diﬀerences in WBC count, hemoglobin level,
platelet count, CRP, ALT, or AST among KD children with
genotypes GG, CG, and CC (Table 8).
3.7. Serum Resistin Concentration. Serum resistin levels were
signiﬁcantly higher in KD patients than control subjects
(20.24 ± 14.32ng/mL versus 8.24 ± 7.88ng/mL, P<0.001;
Figure 1). However, the level was not signiﬁcantly higher in
KD patients with CALs compared to KD patients without
CALs (25.69 ± 17.58ng/mL versus 20.84 ± 13.74ng/mL,
P = 0.25; Figure 2). Serum resistin levels were higher in
the GG group compared to the CG and CC groups amongMediators of Inﬂammation 5
Table 7: RETN (−420C > G) genotype and allele frequency in the groups with responders and nonresponders.
Responders (n = 68) n (%) Nonresponders (n = 23) n (%) P value OR (95% CI)
Allele C 52 (0.388) 16 (0.348) 0.752 1.224 (0.349–4.293)
G 82 (0.612) 30 (0.652)
Genotypes
CC 8 (0.134) 0 (0.000)
0.504 GG 23 (0.333) 7 (0.286)
CG 36 (0.524) 16 (0.714)
Genotypes GG 23 (0.343) 7 (0.304) 0.815 1.25 (0.192–8.144)
CC + CG 44 (0.657) 16 (0.696)
Note: P value is for comparison between groups with responders and nonresponders
Table 8:Associationbetween RETN(−420C > G)alleles andclinical andlaboratorydataobtained fromchildren withtheKawasaki disease.
Clinical and laboratory data GG CC + CG P
Hemoglobin (g/L) 107.5 ±7.43 110.13 ±2.34 0.240
Platelet (103/uL) 329.43±74.28 461.77 ±200.29 0.102
WBC (103/uL) 13.04 ±5.18 13.78 ±6.38 0.771
RBC (106/mm3)3 .89 ±0.39 3.93 ±0.41 0.79
AST (U/L) 42.16 ±22.77 68.70 ±103.77 0.545
ALT (U/L) 82.33 ±71.54 93.00 ±123.81 0.844
CRP (mg/dL) 45.57 ±35.44 37.42 ±33.15 0.585
ESR (mm/hr) 48.38 ±27.42 53.42 ±28.34 0.674
Resistin (ng/mL) 23.30 ±12.35 19.49 ±16.22 0.550






























(KD) and control subjects.
KD patients, but the diﬀerence was not signiﬁcant (Figure 3,
P>0.05).
4. Discussion
To our knowledge, this is the ﬁrst study to examine the
association between the RETN −420C > Gp o l y m o r p h i s m
and the risk of KD. We herein investigated whether the
RETN −420C > G promoter polymorphism could be
associated with the development of CALs in KD patients.
Among our study population, we found no signiﬁcant
diﬀerence in RETN −420C > G genotypes between KD
and control subjects. In addition, there was no association
between the RETN −420C > G gene polymorphism and
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Figure 2: Serum resistin levels in the Kawasaki disease (KD)
children with and without CALs.
our analysis identiﬁed a statistically signiﬁcant association
between the RETN −420C to G mutation and the increased
risk of iKD. These ﬁndings suggest that the tested RETN
−420C > G polymorphism might not be associated with
the development of KD and CALs in Chinese children with
KD. However, the diagnosis of iKD is challenging but can
be supported by the presence of RETN (−420C > G) GG
genotype or G allele.
In our control group, the −420G allele frequency was
observed at 65.2%, which was higher than that reported in
the study by Xu et al. (>31% in Hong Kong, China) [21].
Thisinconsistencymightreﬂecttheselectionbias.TheRETN
−420C > G polymorphism is located in the promoter region



























19.49 ±16.22 23.30 ±12.35
CC (n = 16) GC (n = 42) GG (n = 33)
Figure 3: Serum resistin levels in Kawasaki disease (KD) children
with CC, GC, and GG genotypes.
associations between the RETN −420C > Gp o l y m o r p h i s m
and coronary artery disease, although the results are incon-
sistent. Kunnari et al. investigated the associations between
the RETN −420C > G polymorphism and cerebrovascular
disease in Finnish type 2 diabetes patients [17]. Their study
demonstrated that the GG homozygote was associated with
a higher frequency of cerebrovascular disease, suggesting a
potential role for the RETN −420C > Gp o l y m o r p h i s mi n
atherogenesis. In recent paper Tang and colleagues discuss
an association of the G allele with cardiovascular disease
in a Chinese population [16]. In contrast to Tang et al.,
Michael et al. could not ﬁnd that this polymorphism is a risk
factor for cardiovascular disease [22]. In the present study,
weconductedahospital-basedcase-controlstudytoexamine
the association between the RETN −420C > Gp o l y m o r -
phism and the risk of KD. Among our study population,
we found no signiﬁcant diﬀerence in RETN −420C > G
genotypes between KD and control subjects. In addition,
there was no association between the RETN −420C >
G gene polymorphism and development of CALs in the
enrolled KD patients. However, we found increased risk of
iKD in subjects with RETN (−420C > G) GG genotype
compared with carriers of other genotypes (CC and CG).
In recent years, patients who did not fulﬁll all the clinical
criteria of KD have been described. Moreover, iKD group
is associated with an increased risk of coronary aneurysm
[23, 24]. Given the diagnostic diﬃculties, the diagnostic
criterion of incomplete KD cases remains unclearly deﬁned.
Alternatively,thepresenceofcoronaryarteryaneurysmsmay
be the only deﬁnitive means to diagnose iKD. Fortuitously,
our study found that signiﬁcantly more iKD than cKD
patients were homozygous for the G allele. Therefore, the
diagnosis of iKD is challenging but can be supported by the
presence of RETN (−420C > G) G allele or GG genotype.
It has been reported that the RETN −420C>G variant
could gain the ability to bind the Sp1/3 transcription
factor, which might markedly enhance RETN gene promoter
activity and increase transcription of the RETN gene [15].
Previous studies have also demonstrated that the RETN
−420G allele was associated with higher expression of
resistin mRNA and resistin levels in humans [13, 14].
Moreover,theexpressionofresistinmRNAinmonocyteswas
reported to be highest in subjects with the RETN −420GG
genotype, followed by CG and CC [25]. We observed that
serum resistin levels were higher in the CG + GG group
compared to the CC group in Chinese children with KD,
but this diﬀerence did not reach statistical signiﬁcance.
This association is also supported by a study reported by
Menzaghi et al. in an analysis of Caucasian subjects [26].
Most recently, Hivert et al. also reported that SNP-420 was
not associated with circulating resistin in Caucasian subjects
[27]. In their meta-analysis, which included Caucasians,
Japanese, and Korean subjects, SNP-420 was found to be
associatedwithplasmaresistin withsigniﬁcantheterogeneity
among the groups studied, suggesting that ethnic diﬀerences
may be a factor [27]. The present study is limited by
the relatively small study population and the possibility
of linkage disequilibrium with an unknown risk allele in
or near the RETN gene. Further large-scale studies will
be necessary to examine associations between RETN gene
polymorphismsandserumresistinlevelsinKDpatientswith
and without CAL. In addition, it is unknown whether or not
thepolymorphismexaminedhereinplaysafunctionalrolein
resistin expression.
Some studies have also shown correlations between
KD with CALs and inﬂammatory parameters such as CRP
[28, 29].Furthermore,interleukin(IL)-6andtumornecrosis
factor-α levels were also signiﬁcantly higher in KD patients
with coronary aneurysm compared to those without coro-
nary aneurysm [30]. In recent years, the role of resistin in
the pathogenesis of cardiovascular and inﬂammatory disease
has become of increasing interest. Resistin has been shown
to be involved in the process of inﬂammation, which is
known to play a crucial role in the development of coronary
artery disease [8]. In previous literature, it is shown that
resistin is induced by lipopolysaccharides (LPSs) and TNF-
alpha in macrophages in vitro and is markedly increased
in leukocytes and plasma in vivo during endotoxaemia
[31]. It is reported to strongly upregulate the expression
of proinﬂammatory cytokines including interleukin (IL)-
6 and tumour necrosis factor (TNF)-α in human and is
associated with many inﬂammatory markers including C-
reactive protein and intercellular cell-adhesion molecule
(ICAM)-1 [9]. Resistin also competes with LPS to bind TLR-
4 (which is a toll-like receptor on mononuclear cells) so
it acts like a proinﬂammatory cytokine [32].Therefore, it
was reasonable to assume that serum resistin levels were
signiﬁcantlyhigherinKDpatientsthancontrolsubjects.Our
ﬁnding of the increased levels of resistin from KD patients is
in agreement with the previous research in Japanese patients
with KD [33]. In a recent study, the results suggest that high
serum resistin level may be a predictor of nonresponsiveness
to intravenous immune globulin therapy [34]. However,
there were no obvious diﬀerences in the genomic frequen-
cies and genotype between responders and nonresponders
Therefore,morestudiesareneededtoconﬁrmthehypothesis
that the association between resistin concentration and the
nonresponders.
We also estimated the impact of the RETN −420C > G
polymorphism on the clinical parameters in KD patients.
Our data showed that there were no signiﬁcant diﬀer-
ences between the genotypes with respect to WBC count,
hemoglobin level, platelet count, CRP, ALT, and AST inMediators of Inﬂammation 7
KD patients. Several previous studies have focused on
the associations between the RETN −420C > Gp o l y -
morphism and CRP levels, and no consistent results have
been reported. Tang and associates have demonstrated that
the RETN −420C > G polymorphism leads to increased
CRP concentrations in patients with stable CAD, suggesting
a potential involvement of the protein in atherogenesis
[35]. However, we did not ﬁnd any signiﬁcant correlations
between the RETN −420C > G polymorphism and CRP.
The inconsistency between these ﬁndings may be due to the
diﬀerence in the region origin of the study populations.
The potential limitations of our study should be noted.
First, hospital-based controls were used, possibly resulting
in selection bias. However, the genotype distribution of
controls in our study was compatible with the Hardy-
Weinberg expectations. Second, our study was conducted in
a Chinese population, and the data should be extrapolated
to other ethnic groups with caution. Third, the sample size
of the present study was relatively small, possibly resulting
in wide conﬁdence intervals that approach unity. Larger
studies are required to conﬁrm our observations. Lastly,
we did not get the data of BMI (body mass index), and
BMI is an important factor which may independently eﬀect
resistin levels [31]. However, this internally consistent pilot
study certainly provides valuable insights and interesting
information and may serve to guide future studies in this
area.
In conclusion, this study demonstrates for the ﬁrst time
that the RETN −420C > G polymorphism is associated with
the presence of iKD. Although resistin appears to play a role
in KD, the RETN (−420C/G) gene polymorphism does not
appear to be associated with the development of KD or CAL
in Chinese children. However, further large-scale studies
will be needed to ﬁrmly establish the relationships between
RETN gene polymorphisms and CAL in KD. Collectively,
this work will provide important new insights into the KD
pathology and may provide new targets for the design of
novel diagnosis measures for iKD.
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